Showing results (111-120 of 747) with videos related to

Sort By:
Pageof 75
American Heart Journal|August 17, 2004
Slowing the progression of diabetic nephropathy and its cardiovascular consequencesPeter A McCullough, George L Bakris, William F Owen, et al.
Expert Opinion on Investigational Drugs|May 22, 2008
Rivaroxaban, an oral direct factor Xa inhibitorJonathan P Piccini, Manesh R Patel, Kenneth W Mahaffey, et al.
Pediatrics|November 3, 2005
Heart rate characteristics: novel physiomarkers to predict neonatal infection and deathM Pamela Griffin, Douglas E Lake, Eric A Bissonette, et al.
Pediatric Research|March 21, 2003
Abnormal heart rate characteristics preceding neonatal sepsis and sepsis-like illnessM Pamela Griffin, T Michael O'Shea, Eric A Bissonette, et al.
The Journal of Bone and Joint Surgery. American Volume|April 3, 2015
Baseline predictors of health-related quality of life after anterior cruciate ligament reconstruction: a longitudinal analysis of a multicenter cohort at two and six yearsWarren R Dunn, Brian R Wolf, Frank E Harrell, et al.
The American Journal of Medicine|January 13, 2004
Economic effects of beta-blocker therapy in patients with heart failurePatricia A Cowper, Elizabeth R DeLong, David J Whellan, et al.
Journal of Interventional Cardiology|February 6, 2013
Would tirofiban have been shown non-inferior to abciximab had the TENACITY trial not been terminated for financial reasons?Peter B Berger, Judson B Williams, Vic Hasselblad, et al.
JAMA Network Open|October 8, 2020
Development and Validation of a Natural Language Processing Tool to Generate the CONSORT Reporting Checklist for Randomized Clinical TrialsFan Wang, Richard L Schilsky, David Page, et al.
American Heart Journal|June 6, 2020
Levels of evidence supporting drug, device, and other recommendations in the American Heart Association/American College of Cardiology guidelinesAlexander C Fanaroff, Marat Fudim, Robert M Califf, et al.
Statistics in Medicine|October 12, 2007
Analysis of longitudinal laboratory data in the presence of common selection mechanisms: a view toward greater emphasis on pre-marketing pharmaceutical safetyJonathan S Schildcrout, Cathy A Jenkins, Jack H Ostroff, et al.
Pageof 75